Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00710021 · ClinicalTrials.gov registry record · Phase 2
Vitamin D3 in Systemic Lupus Erythematosus
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
NCT00710021 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 57 participants.
The verdict
NCT00710021, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
Study Summary
The purpose of this study is to explore the impact of vitamin D3 on the expression of alpha interferon (IFN alpha) expression in systemic lupus erythematosus (SLE) patients with vitamin D deficiency.
Interventions
- DRUG Vitamin D3
- DRUG Vitamin D3 placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2008-11 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00710021
The ClinicalTrials.gov registry entry for NCT00710021 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vitamin D3 is the first listed.
NCT00710021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00710021 about?
NCT00710021 is a clinical study titled "Vitamin D3 in Systemic Lupus Erythematosus". The purpose of this study is to explore the impact of vitamin D3 on the expression of alpha interferon (IFN alpha) expression in systemic lupus erythematosus (SLE) patients with vitamin D deficiency.
What is the current status of trial NCT00710021?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2008-11. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00710021?
The interventions under investigation include: Vitamin D3 (DRUG), Vitamin D3 placebo (DRUG).
Who is sponsoring clinical trial NCT00710021?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.